 |
|
|
| |
Maraviroc Combined Analysis & MOTIVATE 2 (Europe, Australia, USA): 24 week Results
|
| |
| |
Reported by Jules Levin
CROI, Feb 28, 2007, LA
Demographics and Baseline Characteristics
Mean age: 45-47 yrs
Male: 84-89%
White: 82-87%
Median CD$ count: 174-182
Mean HIV-1 RNA: 4.84-4.89 log
Fuzeon in OBT: 45% in placebo, 62% in MVC.
Mean Change in HIV-1 RNA from Baseline at Week 24
Placebo+OBT: -0.93
MVC QD+OBT: -1.95 (difference: -1.02, 97.5% CI: -1.43, -0.62)
MVC BID+OBT: -1.97 (difference: -1.04, 97.5% CI: -1.44, -0.64)
Percentage of Patients with Undetectable HIV-1 RNA
<400 c/ml: 61.3% MVC bid; 55.5% MVC qd, 23.1% placebo (p<0.001; versus placebo+OBT)
Approximately 8% of patients had a change in tropism result between screening and baseline, demonstrating the change in background tropism over a 4Ð6 week period in this population
Response to maraviroc treatment in these patients was consistent with the results of study A4001029 in patients with D/M-tropic virus (XVI IAC 2006, Abs THLB0215)
Data excludes patients who had no tropism result at time of failure and patients with non-R5 virus at baseline.
|
| |
|
|
|
|
|
